ClinicalTrials.gg
Active, not recruitingNCT07408388Updated Feb 17, 2026

Pulse Oximeter Accuracy During Stable Hypoxia Plateaus

An observational study in Hypoxia, sponsored by Nihon Kohden. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Nihon Kohden · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
48
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hypoxia by Nihon Kohden — 2 open to participants now, 4 under way, none of them phase 3. Hypoxia · Nihon Kohden.

Planned enrollment
2nd of 10
48 · median 12
Started
2025
with 1 other
Observational
10 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Hypoxia by Nihon Kohden, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2025, is one of 10 observational ones, and was the 9th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

2 of the 10 studies in Hypoxia by Nihon Kohden are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hypoxia by Nihon Kohden, or all of them as a file.
02

Study summary

The aim of this study is to determine the accuracy of devices called pulse oximeters, which measure blood oxygen by shining light through fingers, ears or other skin, without requiring blood sampling. Study will be used with healthy volunteers at rest.

Read the detailed description

This study will evaluate the accuracy of Nihon Kohden pulse oximeters and sensors in measuring arterial oxygen saturation (SpO₂) in healthy adult volunteers. Subjects will undergo controlled reductions in blood oxygen levels (down to 70%) while SpO₂ readings from the test devices are compared to reference values from arterial blood samples. The study is designed to meet current ISO and FDA requirements, and results may be used to support regulatory submissions. Data will be analyzed for overall accuracy and potential differences by skin tone and sex.

03

Conditions studied

  • Hypoxia

Browse trials for

Keywords

  • Hypoxia
  • Pulse oximetry
  • SpO2
  • Pulse oximeter
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy adult volunteers. At least 48 new subjects will be enrolled. Subjects will be selected with reference to ISO and FDA requirements to ensure appropriate representation across skin tone categories (Monk Skin Tone scale) and sex.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is male or female, aged 18 to 50.
  • The subject is in good general health with no evidence of any medical problems
  • The subject is fluent in both written and spoken English.
  • The subject has provided and is willing to comply with the study procedures.

Exclusion criteria

Exclusion Criteria:

  1. The subject has a above 40
  2. The subject has blood pressure above 160 systolic or 95 diastolic
  3. The subject has a known history of heart disease, lung disease, kidney or liver disease.
  4. Diagnosis of asthma, sleep apnea, or use of CPAP.
  5. Subject has diabetes.
  6. Subject has a clotting disorder.
  7. The subject has a hemoglobinopathy or history of anemia, per subject report or the first blood sample, that in the opinion of the investigator, would make them unsuitable for study participation. (COHb\<3%, MetHb\<2%, ctHb>10 g/dL).
  8. The subject has any other serious systemic illness.
  9. The subject has smoked in the last 12 hours.
  10. Any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigators would interfere with the sensors working correctly.
  11. The subject has a history of fainting or vasovagal response.
  12. The subject has a history of sensitivity to local anesthesia.
  13. The subject has a diagnosis of Raynaud's disease.
  14. The subject has unacceptable collateral circulation based on exam by the investigator (Allen's test).
  15. The subject is pregnant, lactating or trying to get pregnant.
  16. Subjects who have uneven skin tones at the forehead or the sensor site.
  17. The subject is unable or unwilling to provide or is unable or unwilling to comply with study procedures.
  18. The subject has any other condition, which in the opinion of the investigators would make them unsuitable for the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
48 participants (estimated)
Target follow-up
1 Week
Patient registry
Yes

Groups and cohorts

  • Adult healthy subjects

    Adult healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile in an at rest state

    Device: Pulse Oximeter · Procedure: Induced hypoxia through breathing nitrogen-air-carbon dioxide mixture

Interventions

  • DevicePulse Oximeter

    OLV-4202 pulse oximeter ((SW version: 01-17)

  • ProcedureInduced hypoxia through breathing nitrogen-air-carbon dioxide mixture

    Subjects will be placed in a seated semi-reclined position. Subjects will breathe a nitrogen-air-carbon dioxide mixture to produce the desired level of hypoxemia. Stable, safe and controlled hypoxia is obtained by breath-by-breath analysis of respiratory gas using a gas analyzer that permits the inspired gas mixture to be adjusted to achieve the desired degree of blood oxygen saturation. Study is observational to see response of pulse oximeter. Intervention (above) is not therapeutic, rather is simply used to vary oxygen levels in subjects.

06

What researchers measure

Primary outcomes

  1. Accuracy of Sensor Oxygen Saturation by Arms Calculation

    Accuracy will be determined by comparing the noninvasive blood oxygen saturation measurement of the pulse oximeter (SpO2) to that obtained from a blood sample (SaO2) and calculating the arithmetic root mean square (Arms) error value as follows: Arms = Square root (sum of n samples of ((SpO2i - SRi) squared) / n)

    Time frame: Up to 15 min

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Company confidential.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 30 industry-sponsored observational studies under Hypoxia, half reached primary completion within 0 months of starting (the median), counting those still running; a quarter within 0 and three quarters within 2.

Counting every sponsor, half of 155 studies reached it within 14 months; a quarter within 3 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2025
First posted
Feb 13, 2026
StartActual
Dec 3, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07408388
Lead sponsor
Nihon Kohden
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Dec 3, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Greg Stratmann, MD, PhD
principal investigator · University of California, San Francisco, Department of Anesthesia and Perioperative Care

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion